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Abstract 
Prostate cancer is a major cause of male death worldwide and the identification of new and improved 
treatments is constantly required. Among the available options, different non-steroidal androgen 
receptor (AR) antagonists are approved also to treat castration-resistant forms. Most of these drugs 
show limited application due to the development of resistant mutants of their biological target. 
Following docking-based studies on a homology model for the AR open antagonist conformation, a 
series of novel 3,5-bis-trifluoromethylphenyl compounds was designed with the aim to improve the 
antiproliferative activity of anti-androgen drugs bicalutamide and enzalutamide. The new structural 
modifications might impede the receptor to adopt its closed agonist conformation also in the presence 
of adaptive mutations. 
Among the novel compounds synthesised, several displayed significantly improved in vitro activity in 
comparison with the parent structures, with IC50 values in the low micromolar range against four 
different prostate cancer cell lines (LNCaP, VCaP, DU-145, 22Rv1). Selected hits demonstrated full 
AR antagonistic behaviour and promising candidates for further development were identified. 
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Prostate cancer (PC) represents a major cause of male death worldwide and it is the second most 
common cancer for males, the fourth most common cancer overall.1 Currently, among the several 
treatment options available, androgen deprivation is one of the main strategies to treat the disease at 
various stages of its development.2 Flutamide (1) (in its active form as hydroxyflutamide (2)), 
bicalutamide (3) and enzalutamide (4) are non-steroidal androgen receptor antagonists approved for the 
treatment of PC (Figure 1). In many cases, these anti-androgens become ineffective after few years of 
treatment due to the emergence of different mutations on the AR, which cause the anti-androgen 
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compounds to function as agonists.2 
In order to improve the antiproliferative properties of standard anti-androgens 3 and 4, and to possibly 
impede the receptor to adopt its closed agonist conformation in the presence of adaptive mutations, 
diverse new analogues were designed to increase the molecule occupational volume in proximity to the 
receptor helix 12, responsible for the closure movement to the agonist conformation, with the aim to 
impede this conformational change. Specifically, different hydrophobic aromatic substituents were 
explored with docking studies, and in particular attention was focused on fluorinated groups, in order to 
take advantage of the potential of fluorine to enhance the pharmacological properties and drug-like 
characteristics of compounds.3 A 3,5-bis-trifluoromethyl group was identified as the best substituent for 
aromatic ring B of the parent structures to achieve this result (Figure 1). The new analogues showed a 
marked improvement in in vitro antiproliferative activity on a range of human PC cell lines (VCap, 
LNCaP, DU-145 and 22Rv1), reaching sub-micromolar IC50 values. In addition, full AR antagonistic 
effect was observed for selected compounds and preclinical candidates were identified. 
 
Figure 1. Structure of AR antagonists in the market for the treatment of PC and their proposed modifications. 
 
A homology model of the human WT-AR open conformation was built using a single template 
approach in MOE2015.4 The crystal structure of the progesterone receptor in its open antagonist form 
(PDB ID: 2OVM) was used as template (54% sequence identity with the human AR).5 Docking of (R)-
bicalutamide, enzalutamide and of the newly designed modifications was performed in the ligand 
binding domain (LBD) of the AR model using Plants docking software.6 The predicted binding mode 
found for the parent compounds revealed the presence of free occupational space in the model structure 
in proximity to helix 12. As shown in Figure 2a, in silico studies suggest that the best substituent to fill 
this space is a 3,5-bis-trifluoromethyl group on aromatic ring B of the standard compounds. Due to the 
much bigger occupational volume in comparison with the 4-F substituent of bicalutamide, this 
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modification might impede the receptor closure even in the presence of adaptive mutations, such as the 
W741L mutation, the most common for bicalutamide.7 As a further indication of this potential effect, 
docking of the newly designed compounds on the crystal structure of the complex bicalutamide-
W741L AR (PDB ID 1Z95), which corresponds to the receptor closed conformation, reveals the 
presence of steric clashes between the new bis-trifluoromethyl portion of the molecule and helix 12 
(Figure 2b). 
 
Figure 2. Predicted binding mode of 25a in the AR homology model (a) and in the bicalutamide-W741A AR closed 
conformation crystal structure 1Z95 (b). The bis-CF3 aromatic substituent in ring B shows major clashes (red grid) with the 
protein surface (grey grid) of the closed AR structure, indicating that it might impede the AR closure movement even in the 
presence of adaptive mutations. 
 
Along with the insertion of a 3,5-bis-trifluoromethyl group in aromatic ring B of the parent structures, 
its replacement with a bulkier 3,5-di-tert-butyl substituent was also envisaged (compound 30f). 
Moreover, ring A was explored as well for the repositioning and replacement of its original substituents 
with a bis-CF3 function. All planned modifications were carried out according to an optimised three or 
four-step synthetic pathway, adapted from literature procedures,8-14 summarised in Schemes 1 and 
Scheme 2. 
Racemic bicalutamide derivatives, along with racemic bicalutamide,10 were prepared by reacting 
methacryloyl chloride (5) with substituted anilines 6-11 in dimethylacetamide (DMA) to obtain 
phenylacrylamides 12-17, which were converted into the corresponding epoxides 18-23 in the presence 
of a large excess of hydrogen peroxide and trifluoroacetic anhydride in dichloromethane. Opening of 
the epoxide rings of 18-23 with substituted phenols or thiophenols gave a series of ethers 30-34 and 
thioethers 24-29. Thioethers 24-27 and 29 were oxidized to the corresponding sulfones 35-39 with 
mCPBA at 25 °C. For the synthesis of R-bicalutamide12 and R-derivatives 41-42, intermediate 40 was 
prepared according to literature,11 and then reacted with the sodium salt of 3,5-bis-CF3-thiophenol in 
tetrahydrofuran to give the desired (R)-thioether 41.12 Oxidation of 41 with mCPBA provided sulfone 
42. Enzalutamide analogues were obtained by the preparation of isothiocyanates 43-46, treating the 
corresponding anilines 6-9 with thiophosgene.13 Strecker reaction of substituted aniline 11 with acetone 
and trimethylsilyl cyanide generated the desired cyanoamine 47, which was reacted with 
isothiocyanates 43-46 in DMF followed by HCl and MeOH addition to give the desired thiohydantoins 
48-51. Thiohydantoin 54 was prepared by heating intermediate 53, obtained according to literature 
procedures,14 with isothiocyanate 52 in a mixture of DMSO and isopropylacetate (iPAC) at 85 °C for 
14 hours. Standard enzalutamide was also prepared according to this procedure.14 All final compounds 
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were fully characterised by 1H NMR, 13C NMR, 19F NMR and HRMS. Purity >95% was confirmed by 
HPLC (see Supplementary Material). 
 
Scheme 1 Synthetic pathways for the synthesis of racemic and R-bicalutamide analogues adapted from reported procedures.8-12 
Reagents and conditions: (a) 5 (8 equiv.), DMA, RT, 3 h (77-95%); (b) H2O2 (4 equiv.)/(CF3CO)2O (5 equiv.), DCM, RT, 24 h 
(60-86%); (c) NaH (1.2 equiv.), phenol or thiophenol (1.2 equiv.), THF, RT, 24h (29-89%); (d) mCPBA (1.4 equiv.), DCM, RT, 
4-6 h (40-89%); (e) 3,5-bis-CF3-thiophenol (1.2 equiv.), 60% NaH (1.2 equiv.), THF, RT, 24 h (75%);  (f) mCPBA (1.4 equiv.), 
DCM, RT, 6 h (68%). 
 
Scheme 2. Synthetic strategy toward enzalutamide derivatives. Adapted from literature procedures.13, 14 Reagents and conditions: 
(a) CSCl2 (1.5 equiv.), NaHCO3, H2O, DCM, RT, 24 h (98-100%); (b) TMSCN (5.1 equiv.), acetone, 80 °C, 12 h (80-97%); (c) 
DMF, RT 48 h, followed by HCl, MeOH, reflux, 6 h (10-51%). d) DMSO, iPAc, 85 °C, 14 h (67%). 
 
All newly synthesised compounds were evaluated for their antiproliferative effect in an in vitro 2D 
monolayer assay using four human prostate cancer cell lines (Table 1, absolute IC50 in µM). LNCaP, 
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VCaP and 22Rv1 cell lines exhibit some androgen sensitivity, whereas DU-145 is hormone-insensitive 
(Supporting Information, section S.3). 
The activity of reference compounds 3 and 4 is consistent with previously reported data.15-17 As recent 
research studies carried out in our group have shown the lack of significant difference in 
antiproliferative activity between racemic and R-bicalutamide analogues,18 the major part of our new 
bicalutamide-derived structures have been prepared as racemic mixtures. Most of the new derivatives 
performed better than standard bicalutamide, significantly improving its antiproliferative activity up to 
60-fold (overall antiproliferative activity in the four cell lines reported as geometric mean). Active 
inhibitors showed sigmoidal concentration-effect curves with total cell kill at high concentrations 
(Supplementary data). 
 
 Scaffold 1             Scaffold 2      
Compound Scaffold Ar (B ring) X R (A 
ring) 
Absolute IC50 (µM) 
 
    22Rv1 DU-
145 
LNCaP VCaP Geom.mean 
R,S-
Bicalutamide 
1 
 
4-F-Ph SO2 4-CN, 3-
CF3 
49.58 49.20 45.27 68.37 52.42 
3 (R-
Bicalutamide) 
1 4-F-Ph SO2 4-CN, 3-
CF3 
46.25 45.41 45.20 51.61 47.05 
24a 1 3,5- CF3-Ph S 4-CN, 3-
CF3 
1.90 2.85 2.34 2.73 2.43 
25a 1 3,5- CF3-Ph S 4- NO2, 
3-CF3 
1.50 2.78 1.50 1.53 1.76 
26a 1 3,5-CF3-Ph S 4-CN, 2-
CF3 
4.65 9.09 7.76 6.65 6.84 
27a 1 3,5- CF3-Ph S 4-NO2, 
2-CF3 
2.29 3.38 3.11 3.52 3.03 
28a 1 3,5-CF3-Ph S 4-CF3 9.75 16.39 9.61 9.88 11.10 
29b 1 3-CF3-Ph S 3,5-CF3 9.67 10.03 8.75 9.86 9.56 
29c 1 2-CF3-Ph S 3,5-CF3 4.37 8.66 3.57 3.84 4.78 
29d 1 3-OCF3-Ph S 3,5-CF3 6.42 9.61 7.76 9.29 8.17 
29e 1 2-OCF3-Ph S 3,5-CF3 2.94 6.41 2.91 2.90 3.55 
30a 1 3,5-CF3-Ph O 4-CN, 3-
CF3 
2.64 4.70 3.01 2.47 3.10 
30f 1 3,5- tBu-Ph O 4-CN, 3-
CF3 
2.27 3.15 2.67 2.98 2.69 
31a 1 3,5- CF3-Ph S 4-NO2, 
3-CF3 
1.09 2.90 0.99 1.66 1.68 
32a 1 3,5-CF3-Ph O 4-CN, 2-
CF3 
4.07 8.05 3.56 4.77 5.11 
33a 1 3,5-CF3-Ph O 4-NO2, 
2-CF3 
16.10 11.64 23.98 23.73 14.18 
34a 1 3,5-CF3-Ph O 4-CF3 8.49 9.23 3.35 4.15 5.75 
35a 1 3,5-CF3-Ph SO2 4-CN, 3-
CF3 
3.11 5.58 2.86 6.21 4.19 
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36a 1 3,5- CF3-Ph SO2 4-NO2, 
3-CF3 
2.15 5.26 2.10 3.30 2.98 
37a 1 3,5-CF3-Ph SO2 4-CN, 2-
CF3 
n.d. n.d. n.d. n.d. n.d. 
38a 1 3,5-CF3-Ph SO2 4-NO2, 
2-CF3 
2.41 3.05 3.09 7.11 3.57 
39b 1 3-CF3-Ph SO2 3,5-CF3 10.27 11.48 9.50 9.98 10.28 
39c 1 2-CF3-Ph SO2 3,5-CF3 9.45 11.02 8.51 8.55 9.33 
39d 1 3-OCF3-Ph SO2 3,5-CF3 12.84 14.11 9.34 9.99 11.42 
39e 1 2-OCF3-Ph SO2 3,5-CF3 8.99 12.91 8.02 9.95 9.81 
41 1 3,5- CF3-Ph S 4-CN, 3-
CF3 
1.13 2.66 0.79 0.84 1.19 
42 1 3,5- CF3-Ph SO2 4-CN, 3-
CF3 
2.50 6.36 1.99 4.11 3.38 
4 
(Enzalutamide) 
2 3-F,4-
CONHMe-Ph 
- 4-CN, 3-
CF3 
31.76 32.27 11.47 53.04 28.10 
48 2 3,5- CF3-Ph - 4-CN, 3-
CF3 
n.d. n.d. n.d. n.d. n.d. 
49 2 3,5- CF3-Ph - 4-NO2, 
3-CF3 
20.20 18.12 9.93 28.44 17.93 
50 2 3,5- CF3-Ph - 4-CN, 2-
CF3 
n.d. n.d. n.d. n.d. n.d. 
51 2 3,5- CF3-Ph - 4-NO2, 
2-CF3 
6.97 10 4.67 18.59 8.82 
54 2 3-F,4-
CONHMe-Ph 
- 3,5-CF3 26.37 47.86 11.29 19.77 29.78 
Table 1. Antiproliferative activity for bicalutamide/enzalutamide derivatives. All data are mean values from triplicate 
experiments. 
 
In the bicalutamide-derived series of analogues (compounds 24-42), all the newly synthesised 
compounds performed better than the standards in the antiproliferative assay, with the only exception 
being 37a, for which an antiproliferative effect could not be observed due to solubility issues. The 
presence of a 3,5-bis-trifluoromethyl substituent in aromatic ring B seems to strongly affect the 
antiproliferative activity in all four prostate cancer cell lines, with the best results obtained for 41, 
which reaches sub-micromolar IC50 values in two different cell lines (LNCaP and VCaP, both 
androgen-sensitive), 31a, 25a, 24a, 36a, 27a and 30a. Replacement of the bis-CF3 substituent of 30a 
with a bulkier 3,5-di-tert-butyl group (compound 30f) leads to slightly lower IC50 values, which 
indicate activity retention. Insertion of a 3,5-bis-CF3 substituent in ring A of parent bicalutamide 
(compounds 29b-e, 39b-e), according to our modelling studies, would be associated with a better 
occupation of the inner portion of the AR ligand binding domain; this modification, combined with 
optimised substituents for aromatic ring B recently found in our group (unpublished data), is associated 
with a significant activity improvement in comparison with standard bicalutamide for all the new 
derivatives prepared. 
Due to solubility issues, the effect of the modification of ring B of enzalutamide with a 3,5-bis-
trifluoromethyl group could be assessed only for 49 and 51: also in this case, this structural change is 
associated with activity improvement in all four prostate-cancer cell lines, with a particularly 
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significant effect found for 51. Insertion of this substituent on aromatic ring A of enzalutamide 
(compound 54) is associated with activity retention. 
Considering the antiproliferative results obtained across the four different cell lines, the new 
compounds show significant activity also on androgen-insensitive DU-145 cells. Even if the IC50 
values obtained for most of the new compounds are higher in this cell line in comparison with the other 
three, the improved antiproliferative activity suggests the presence of a potential off-target effect, 
besides the canonical anti-androgen mechanism. Nevertheless, the presence of an off-target can be 
speculated also for parent bicalutamide, for which the results obtained in our assay further confirm the 
previously reported lack of selectivity between LNCaP and DU-145 cell lines.15 Due to this last 
consideration, and given the marked improvement in antiproliferative activity associated with the new 
structures, the presence of a potential off-target was not considered a limitation at this stage, while 
further investigations to assess the molecular mechanism underlying this effect will be the object of 
future studies. 
As representative of the new series of compounds, 25a and 36a were evaluated for their 
antagonist/agonist effect on the AR using the GeneBLAzer® Betalactamase reporter technology for 
Nuclear receptors (NRs), to assess whether the antiproliferative activity found is correlated with any 
interference with the AR function.19 Both compounds were found to be full antagonists of the androgen 
receptor in a single concentration antagonism experiment (10µM concentration, antagonistic effect > 
80%), reducing the receptor activation induced by the standard agonist R1881.20,21 A 10-concentration 
antagonism assay showed that 25a possess an antagonistic IC50 in the same range of (R)-bicalutamide 
and enzalutamide (Table 2). The IC50 value found for (R)-bicalutamide is comparable with previously 
reported values in similar assays.22,23 
 
Compound Antagonistic effect (%)* IC50 (µM)** Agonistic effect (%)*** 
3 (R-Bic.) 83 0.490 5 
4 (Enzal.) 95 0.361 N.E. 
25a 90 0.710 7 
36a 93 3.1 1 
Table 2: AR antagonist/agonist assay results. * Compounds were considered full antagonist if at a single concentration of 10µM 
the reduction of receptor activation by R1881 was greater than 80%; ** Compounds tested at 10 different concentrations; *** 
Compound at 10 µM concentration in absence of R1881 was used. 
 
Despite the fact that 36a shows a significantly improved antiproliferative effect, its action as AR 
antagonist seems to be reduced in terms of inhibitory IC50 in comparison with standard bicalutamide, 
thus indicating the presence of other aspects that contribute to its anti-prostate cancer properties, as 
already observed from the antiproliferative data. As a further confirmation of this potential off-target 
effect, additional in vitro studies on 36a and 41, our most active new analogue, were performed in 
order to evaluate their general cytotoxicity in comparison with 3, along with their metabolic stability 
(Table 3). 
 
Compound Metabolic stabilitya MTT assayb Antiproliferative resultsc 
t1/2 (min) MEC (µM)* AC50 (µM)** IC50 (µM) 
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3 (R-bical)  214 19.2 54.3 47.05 
36a 567 3.6 9.01 2.98 
41 6.49 1.22 2.35 1.19 
Table 3: Metabolic stability and cytotoxicity assay results for selected compounds. a t1/2 calculated in human liver microsomes; 
compounds metabolically stable with no loss of parent detected for the duration of the assay. b MTT assay; compounds 
have been tested at 8 different concentrations. * MEC: minimum effective concentration that significantly crosses vehicle control 
threshold; ** AC50: concentration at which 50% of maximum effect is observed. c Antiproliferative assay results are expressed in 
terms of geometric mean of the four different cell lines. 
 
The MTT cell viability assay was performed in a human hepatocarcinoma (HepG2) cell line, as a 
means to measure the effect of 36a and 41 on cell proliferation and other events that eventually lead to 
cell death.24 Data are reported as minimum effective concentration (MEC) related to a vehicle control 
(DMSO) and AC50. The tested compounds showed a concentration-dependent decrease in formazan 
production across the range studied (data not shown), indicating a decrease in cell viability associated 
with some growth inhibitory and toxic effects. Compared with control (R)-bicalutamide 3, 36a and 41 
are characterized by a higher cytotoxicity, which at least partially correlates with the results obtained in 
the antiproliferative assay. These results might further indicate that the newly prepared analogues, 
besides the canonical AR antagonistic activity, possess an extra effect, which positively contributes to 
their antiproliferative action. The presence of the new bis-CF3 substituent in aromatic ring B seems to 
increase the metabolic stability of the bicalutamide scaffold, as suggested by the t1/2 found for 36a, 
which is 2.6 fold higher than the value found for 3. The presence of the thioether group, which likely 
undergoes rapid oxidation to sulfoxide or sulfone, is the most probable cause of the short half-life of 
41, the most active new derivative found in the antiproliferative assay, thus making the sulfide scaffold 
an unsuitable candidate for further development. 
Due to the promising results obtained in the antiproliferative assay, different in vitro properties were 
evaluated for selected new derivatives (sulfone, ether or thiohydantoin analogues), in order to aid the 
identification of pre-clinical candidates. In particular, metabolic stability (t1/2), plasma protein binding 
and cardiotoxicity were considered (Table 4). 
 
Compound Metabolic stabilitya PPBb Cardiotoxicityc 
 
t1/2 (min) % bound % hERG inhib. At 25 µM 
3 (R-bical)  214 9624 n.d. 
30a 1930 94.7 7.64 
39e 290 78.3 13.4 
42 Metabolically stable 99.9 29.3 
51 71.5 99.9 9.44 
Table 4: Metabolic stability, plasma protein binding and cardiotoxicity assay results for selected compounds. a t1/2 calculated in 
human liver microsomes; compounds metabolically stable with no loss of parent detected for the duration of the assay. b 
Plasma protein binding assay; results are expressed in terms of mean % bound from duplicate experiments. c Cardiotoxicity 
expressed in terms of % hERG inhibition at 25 µM compound concentration. 
 
Except for 51, the compounds analysed are characterised by an increased metabolic stability in 
comparison with standard bicalutamide. The tested analogues share a high affinity for human serum 
albumin, with values similar to the ones of R-bicalutamide found for all except 39e. Finally, none of 
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the compounds analysed showed any significant cardiotoxic effect (no IC50 could be evaluated). As a 
combination of its in vitro properties and antiproliferative profile in the four prostate-cancer cell lines, 
42 has been chosen as pre-clinical candidate for the treatment of prostate cancer and will be evaluated 
in 22Rv1 prostate cancer mice models. In particular, 42 is one of the most active compounds identified 
in the antiproliferative assay, with an IC50 of 1.99 µM in the LNCaP cell-lines, the most active among 
the new sulfone derivatives. Being a sulfone this compound is also associated with the highest 
metabolic stability observed, and its plasma protein binding is highly similar to parent R-bicalutamide. 
In summary, a novel series of anti-prostate cancer compounds bearing a 3,5-bis-trifluoromethylphenyl 
group have been identified through a rational approach. Most of the new structures showed a 
significant improvement in antiproliferative activity in comparison with the parent compounds against 
four different prostate cancer cell lines. Full AR antagonistic behaviour has been demonstrated for 
selected new structures and a pre-clinical candidate has been identified and is now undergoing further 
exploration.  The biological data obtained so far suggests that the new compounds, besides their AR 
antagonist activity, might possess an off-target effect, which positively contributes to their anti-prostate 
cancer properties. The evaluation of the molecular basis of this extra effect will be the focus of future 
investigations. 
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